Showing results (191-200 of 304) with videos related to

Sort By:
Pageof 31
Translational Oncology|November 20, 2022
Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patientsEmanuela Risi, Camilla Lisanti, Alessia Vignoli, et al.
Oncotarget|January 20, 2018
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysisCarmine De Angelis, Massimo Di Maio, Anna Crispo, et al.
Breast (Edinburgh, Scotland)|April 22, 2018
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) surveyMarta Bonotto, Debora Basile, Lorenzo Gerratana, et al.
Oncogene|September 25, 2025
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trialElena De Mattia, Yoomi Park, Elena Peruzzi, et al.
Infectious Agents and Cancer|June 26, 2020
Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancerValli De Re, Laura Caggiari, Mariangela De Zorzi, et al.
The Lancet. Oncology|October 3, 2014
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trialGunter von Minckwitz, Fabio Puglisi, Javier Cortes, et al.
Critical Reviews in Oncology/Hematology|November 14, 2022
New steps on an old path: Novel estrogen receptor inhibitors in breast cancerMartina Pagliuca, Marco Donato, Agostina Lagodin D'Amato, et al.
Breast (Edinburgh, Scotland)|November 22, 2017
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancerSamuel Martel, Elena Poletto, Arlindo R Ferreira, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 9, 2023
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposureRossana Roncato, Elena Peruzzi, Lorenzo Gerratana, et al.
Future Oncology (London, England)|December 19, 2019
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivityAntonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, et al.
Pageof 31